STIM
Neuronetics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$1.91
+1.33%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.88
From 52W high−42.12%
Volume559145.00
Market cap$145.54M
P/E (TTM)—
P/S (TTM)0.9x
Div yield—
Key dataOct 19, 2026
Open
$1.88
From 52W high
−42.12%
Volume
559145.00
Market cap
$145.54M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.9x
P/E (TTM)
—
RSI (14)
25.8
MomentumView details →
1D Return
+1.33%
YTD Return
+36.16%
SummaryUpdated Jun 1, 2026
Neuronetics, Inc. (NASDAQ:STIM) is a commercial-stage medical technology company founded in 2001 and headquartered in Malvern, Pennsylvania. The company went public in June 2018 and has evolved from a pure medical device manufacturer into a vertically integrated mental health care provider through its 2024 acquisition of Greenbrook TMS. Neuronetics specializes in non-invasive brain stimulation therapies for treating various neurohealth disorders, with a primary focus on depression treatment through its flagship NeuroStar Advanced Therapy System.
Similar companies
Latest newsMore news →
Neuronetics announced the integration of its TrakStar practice management platform with AdvancedMD, marking the first-ever TMS integration with an EHR/EMR system.42d agoNir Naor was appointed Executive Vice President, Chief Financial Officer, and Treasurer of Neuronetics, Inc., effective July 23, 2026, and subsequently became principal financial and accounting officer on August 12, 2026, succeeding Francis X. Brown III as interim principal financial and accounting officer.64d ago